TP53 mutations are associated with CD19− relapse and inferior outcomes after blinatumomab in adults with ALL

Abstract: Despite the success of the CD19 × CD3 T-cell engager blinatumomab in B-cell acute lymphoblastic leukemia (B-ALL), treatment failure is common and can manifest with antigen loss and extramedullary disease (EMD) relapse. To understand the impact of leukemia genetics on outcomes, we reviewed...

詳細記述

書誌詳細

主要な著者:	Ibrahim Aldoss, Shanpeng Li, Jianying Zhang, Mary C. Clark, Vaibhav Agrawal, Hoda Pourhassan, Paul Koller, Ahmed Aribi, Haris Ali, Amanda Blackmon, Salman Otoukesh, Karamjeet Sandhu, Brian Ball, Shukaib Arslan, Andrew Artz, Idoroenyi Amanam, Monzr M. Al Malki, Amandeep Salhotra, Tibor Kovacsovics, Lindsey Murphy, Michelle Afkhami, Dat Ngo, Jose Tinajero, Zhaohui Gu, Pamela S. Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Stephen J. Forman, Vinod Pullarkat
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2025-05-01
シリーズ:	Blood Advances
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S2473952925000333
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!